Advertisement
Advertisement
U.S. markets open in 4 hours 10 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
190.38-3.11 (-1.61%)
At close: 04:00PM EDT
190.30 -0.08 (-0.04%)
Pre-Market: 05:00AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Top Triangle

Top Triangle

Previous Close193.49
Open193.04
Bid0.00 x 1000
Ask0.00 x 1000
Day's Range188.42 - 194.46
52 Week Range173.45 - 431.11
Volume1,323,137
Avg. Volume1,443,479
Market Cap29.947B
Beta (5Y Monthly)1.16
PE Ratio (TTM)42.88
EPS (TTM)4.44
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est243.18
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
5% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ILMN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Illumina, Inc.
    Analyst Report: Illumina, Inc.Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
    Rating
    Fair Value
    Economic Moat
    20 days agoMorningstar
View more
Advertisement
Advertisement